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Mixed adenoneuroendocrine carcinoma (MANEC) is a rare malignant neoplasm of a complex pathomorphological 
pattern combining the features of adenocarcinoma with a neuroendocrine component. According to the new 
classification of the World Health Organization (WHO) from 2010, the nomenclature of neuroendocrine neoplasms 
(NEN) was changed using this name for the entire group of neoplasms. The name ‘neuroendocrine tumours’ covers 
highly diversified neoplasms, determined in the pathomorphological comparison as G1 (NET G1) or G2 (NET G2). In 
addition, neuroendocrine carcinomas (NEC) and mixed adenoneuroendocrine carcinomas (MANEC) are differentiated. 
In a search of the the PubMed database, approximately 50 reports about this carcinoma were found, mainly with the 
location in the stomach, lymph nodes, intestines, liver, peritoneum, gallbladder, pancreas, oesophagus. We have not 
found a description of the metastatic lesions typical of MANEC in the meninges, brainstem, and lungs. 
We present the case of a 63-year-old patient who was admitted to the Department of Neurology due to increased dizzi-
ness with accompanying diplopia, headache, nausea, and numbness of the hands. These symptoms appeared one day 
prior to admission, with intensification at night. The patient was initially diagnosed at the Department of Laryngology 
due to deafness of the right ear and deep hearing loss in the left ear four weeks prior to admission to our department. In 
the neurological examination, the following findings were detected: conscious, anxious, dysarthric speech, insignificant 
inspiratory dyspnoea, deafness of the right ear, deep hearing loss in the left ear, pharyngeal and palatal reaction, weak 
tension of the palato-pharyngeal fold, bilateral signs of central damage of the seventh nerve, insignificant deviation of 
the tongue to the left, muscle tone of the limbs without deficit, insignificantly decreased muscle tone in the left limbs, 
ataxia in the lower limbs, bilateral plantar reflex. In the admissions ward, CT examination of the head was performed and  
a hypodense focus in the left cerebral hemisphere, hypodense foci around the frontal horn of the lateral ventricles and 
small malacia cavities at the level of the subcortical nuclei were detected. A lumbar puncture was performed obtaining fluid 
with increased cytosis and a decreased glucose level. On the second day of hospitalisation, the general and neurological 
condition of the patient significantly worsened and a ‘sympathetic storming’ appeared followed by circulatory arrest. The 
patient was efficiently resuscitated, but then there was another sudden cardiac arrest and despite a long period of CPR, 
cardiac and respiratory action was not restored. After pathomorphological examination it was established that the whole 
image corresponded to MANEC located in the stomach, with dissemination mainly to the meninges, brainstem and lungs. 
In differential diagnosis rare causes of diseases must always be taken into consideration. An additional difficulty in 
diagnosing MANEC is a difference in the names depending on literature and country of the origin of the article, as 
well as the lack of Polish equivalents of some names of neoplasms. Only a reliable histopathological analysis is able 
to detect neoplasms from this group. 
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Introduction
Mixed adenoneuroendocrine carcinoma (MANEC) is 
a rare tumour of a complex pattern consisting of adenocar-
cinoma and neuroendocrine components. The incidence 
of neuroendocrine tumours (on the basis of SEER /Surveil-
lance Epidemiology and Results/ database) has increased 
five times over the past thirty years, which is connected 
with better diagnostics. For this reason, it is worth getting 
acquainted with the characteristic signs of this proliferative 
process and the accompanying wide spectrum of clinical 
symptoms. 
Case study
A 63-year-old male patient was admitted to the Depart-
ment of Neurology due to intensified dizziness with accom-
panying diplopia, headache, nausea and numbness of the 
hands. The symptoms appeared one day prior to admission 
with intensification after the night. The patient was initially 
diagnosed at the Department of Laryngology due to deaf-
ness of the right ear and profound hearing loss in the left 
ear four weeks prior to admission to our department (MRI 
of the brain, CT angiography of the head and ultrasound ex-
amination of the internal carotid and vertebral arteries were 
performed, the results of which were normal). Furthermore, 
the patient was not chronically treated. The patient did not 
report allergies or intolerance of any medications or other 
substances. The patient did not follow any diets and he also 
denied any addictions or use of stimulants. The community 
and family interview was unremarkable. On admission, high 
values of arterial pressure (170/110 mmHg) and tachycardia 
(110/min) were observed. In the neurological examination, 
the following were confirmed: patient was conscious, rest-
less, his speech was dysarthric, mild inspiratory dyspnoea, 
deafness of the right ear, profound hearing loss in the left 
ear, pharyngeal and palatal reflexes were present, he was 
weakly flexing the glossopalatine folds, bilateral signs of the 
central damage to nerve VII, insignificant tongue deviation 
to the left side, muscle strength of the limbs without deficit, 
insignificantly reduced muscle tone in the left limbs, lower 
limb ataxia, plantar reflex was bilaterally present. In the ad-
missions ward, CT examination of the head was performed 
and the following were confirmed: a hypodense focus in the 
left hemisphere of the cerebellum, hypodense foci around 
the frontal horns of both lateral ventricles and small malacic 
cavities at the level of subcortical nuclei. A lumbar punc-
ture was performed, obtaining fluid with elevated cytosis 
(66 cells/µL), decreased glucose level (< 20 mg/dL), an in-
creased level of lactic acid (9.6 mmol/L), and an insignificantly 
higher protein level (67 mg/dL). In the CSF smear, the follow-
ing were detected: 2% segmented neutrophils, 6% mesothe-
lial cells, 92% lymphocytes. A RT23 test was performed. In lab-
oratory tests the following were confirmed: hyperthyroidism 
(0.13 µU/mL), higher CRP (3.5) and ESR (49 mm), thrombocytosis 
(546 × 103/µL), leukocytosis (23× 103/µL), decreased uric 
acid (3.0 mg/dL), hyponatremia (133 mmol/L), prolonged 
prothrombin time (12.9 sec.), and increased fibrinogen 
(451 mg/dL). The following were administered in the treat-
ment: ceftazidime, metronizadole, acyclovir, dexamethasone, 
mannitol, enoxaparin, furosemide, atorvastatin, perindopril, 
diazepam, acetylsalicylic acid. A nasogastric tube was inserted 
due to difficulty swallowing. Because of decreased oxygen 
saturation — up to 86% — passive oxygen therapy was admin-
istered. On the second day of hospitalization, the general and 
neurological condition of the patient considerably worsened, 
swallowing problems intensified, sympathetic storming ap-
peared. Despite the administration of beta-blocker infusions, 
it was not possible to reduce the heart rate. Sudden cardiac 
arrest was observed. The patient was efficiently resuscitated 
and afterwards sudden cardiac arrest appeared once again 
and despite the long-term duration of cardiopulmonary resus-
citation, it was not possible to restore heart rate and breathing. 
General autopsy and post-mortem examination of the brain 
were requested. After pathomorphological examination it was 
established that the whole image suggested a neoplasm of 
MANEC type located in the stomach, with metastasis mainly 
to the meninges, brainstem and lungs (Figs. 1–4). 
In the immunohistochemical examination, a positive 
chromogranin marker (CHR) and cytokeratin market CK20 
as well as negative cytokeratin CK 7 marker were confirmed 
(Fig. 5). 
The short period of hospitalization in our department 
did not allow the diagnostics to be broadened with compar-
ative MRI of the brain or other measures. In the subsequently 
obtained test results, a normal level of Borrelia antibodies 
and a negative result of the CSF culture were obtained. 
Description
Mixed adenoneuroendocrine carcinoma (MANEC) is 
a rare tumour of a complex pattern consisting of adeno-
carcinoma and neuroendocrine components. According 
to the new classification of the World Health Organization 
(WHO) from 2010, the nomenclature of the neuroendo-
crine neoplasms (NEN) was changed using this term for 
the whole group of these neoplasms. The term ‘neuroendo-
crine tumours’ (NET) includes well-differentiated neoplasms 
described in the pathomorphological comparison as G1 
(NET G1) or G2 (NET G2). Additionally, we can differentiate 
neuroendocrine carcinomas (NEC) and mixed adenoneu-
roendocrine carcinomas (MANEC). 
Having searched the PubMed database, we have not 
found a description of the metastatic lesions typical of 
MANEC in the meninges, brainstem and lungs. 
The term ‘MANEC’ includes carcinomas with a pattern 
of differentiated adenocarcinoma and neuroendocrine 
carcinoma of high malignancy (alternative historic name). 
Ex-goblet cell carcinoid constitutes a separate clinical and 
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pathological entity which in the past was not included in the 
MANEC group. Neuroendocine tumours (NETs) are charac-
terized by mechanisms of collecting the precursors of bio-
genic amines and expression of specific receptors on their 
cell membranes, which is helpful in locating the tumours 
and determining the treatment strategy. Neoplasms of NET 
Figure 1. Visible infiltration from the signet-ring cells in the meninges 
(autopsy preparation of the patient)
Figure 2. Visible oedema in the brainstem and a focus of 
encephalomacia with infiltration from atypical signet-ring cells 
(autopsy preparation of the patient)
Figure 3. Visible infiltration from atypical signet-ring cells in the 
cerebellar meninges (autopsy preparation of the patient)
Figure 4. Visible histopathological picture of the stomach tumour 
(autopsy preparation of the patient)
Figure 5. A. Visible infiltration from the signet-ring cells in the cerebral meninges after mucicarmine staining for the presence of mucous cell;  
B. Visible positive staining for the presence of non-specific marker of neuroendocrine tumours, i.e. chromogranin A (CgA, chromogranin A),  
i.e. protein which is produced, stored and released from the neuroendocrine tissues
A B
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type are differentiated on the basis of the substances se-
creted by cells, hormonal activity or its lack, clinical signs, his-
topathological features and prognosis. NETs come from the 
endocrine glands (the pituitary gland, parathyroid glands, 
adrenal medulla) and, additionally, from the cells of the dif-
fused endocrine system located in the wall of the alimentary 
tract, pancreas, thyroid, thymus or bronchi. NET tumours 
from the digestive system (gastro-entero-pancreatic neu-
roendocine tumours) constitute the majority of this type of 
tumour (over 60% of all neuroendocrine tumours). Until the 
mid-1990s, various synonyms were used to describe these 
neoplasms, including carcinoid, APUD neoplasm, islet cell 
tumour or tumour of the Kulczycki cells. 
The incidence of neuroendocrine neoplasms (on the 
basis of the data from the SEER database) has increased five 
times over recent years, which is related to better diagnos-
tics. Neuroendocrine neoplasms are diagnosed with similar 
frequency in women and men and the peak incidence takes 
place after the age of 50, only the incidence of GEN neuroen-
docrine neoplasms of the appendix is generally observed 
before the age of 30 [1]. Among neuroendocrine tumours 
of the pancreas, genetically conditioned tumours, e.g. VHL 
(von Hippel-Lindau syndrome), MEN1 (multiple endocrine 
neoplasia type 1) [1] may constitute 10–15%. They appear 
approximately 15 years earlier than sporadic tumours. 
In the updated histopathological classification of GEP- 
-NENs published in 2010, the degree of histological maturity 
of the tumour was considered to be the main element as 
it is — unlike other parameters of the pathomorphological 
assessment of GEP-NENs — mutual for the whole group and 
is based on criteria independent of the tumour location. 
Due to the indolent course of the disease, diagnosis in the 
majority of patients is made as late as in the metastatic stage. 
Clinical signs may be non-specific, and may result from 
tumour mass or (in 20–50% of the cases) substance secreted 
by GEP-NENs [2]. Occurrence of signs dependent on active 
substances is more frequently observed in patients with 
neuroendocrine neoplasms of the pancreas as well as mid-
gut neoplasms (midgut — distal small intestine, appendix 
and an initial part of the large intestine) than in patients with 
tumours coming from the foregut (foregut — stomach, duo-
denum) and the hindgut (distal part of the large intestine 
and rectum) [1]. Clinically, the following are most frequently 
diagnosed: the carcinoid syndrome dependent mostly on 
secretion of serotonin, such as flush, diarrhoea, valvular le-
sions in the right part of the heart, stomach-ache, bronchos-
pastic signs, muscle contractions, telangiectasias, edema, 
cyanosis, myopathy and joint symptoms, which are present 
more rarely. Clinical signs of pancreatic NENs depend on 
the substances produced by particular neoplasms, such 
as insulin, gastrin, glucagon, vasoactive intestinal peptide 
(VIP) or somatostatin. According to the current guidelines of 
the European Neuroendocrine Tumor Society (ENETS) from 
2011, the site of the lesion which is often decisive of clinical 
signs of the disease as well as degree of advancement of 
proliferation process are of great importance [3]. 
From the clinical point of view, unambiguous differen-
tial diagnosis between poorly-differentiated large cell neu-
roendocrine carcinoma, small neuroendocrine carcinoma 
and mixed mixed adenoneuroendocrine carcinoma is not 
necessary. All three neoplasms demonstrate a similar level 
of aggressivity and they are treated in a similar way. The 
exception is MANEC of the oesophagus, the prognosis of 
which is slightly better than that of the two other neoplasms, 
despite the fact that treatment results remain unfavourable 
[4]. In the differential diagnostics, the above-mentioned 
criteria allow differentiation of MANEC from signet-ring cell 
carcinoid and adenocarcinoma, as none of these possess 
a poorly-differentiated neuroendocrine component [5]. 
In MANEC diagnostics, standardization of Ki-67 expres-
sion methods (proliferative activity described with Ki-67 
proliferation index on the basis of the immunohistochemical 
test with the application of MIB1 antibody) as currently — in 
most centres — this test is based on subjective pathomor-
phological assessment (Tab. I). 
It is necessary to note that there is a significant range of 
clinical signs depending on the secretory structures within 
the tumour. 
The treatment process depends on histopathological 
diagnosis. Radical surgical treatment constitutes the only 
effective method and the result depends on the correct pre- 
and intra-operative location of the neoplastic lesion. The 
surgical procedure is possible at each stage of disease ad-
vancement. In the limited disease, this constitutes a chance 
for recovery. In the advanced process — due to specificity of 
NENs — biotherapy with the application of labelled somato-
statin analogues, isotopic radiotherapy, chemotherapy and 
new methods of targeted therapy are used [3]. In the case of 
patients with metastatic lesions limited to the liver, surgery 
with an intent to cure improves prognosis (the five-year sur-
Table I. Types of mixed exocrine-neuroendocrine neoplasms of the 
alimentary tract, classified depending on the malignancy grade [6]
1. Mixed Adenoneuroendocrine Carcinoma (MANEC) 
High grade malignancy 
 — Mixed adenoma/adenocarcinoma — NEC
Middle grade malignancy 
 — Mixed adenocarcinoma — G1/G2 NET*
 — Amphicrine carcinoma
2. Mixed Adenoneuroendocrine Tumour (MANET) — Provisional 
category 
Low grade malignancy 
 — Adenoma — NET
*G1–G2 according to WHO classification; NEC — poorly-differentiated 
neuroendocrine carcinoma; NET — neuroendocrine tumour
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vival rate of patients is 60–80%) and it is a method which is 
preferred over ablation methods [7]. However, qualification 
of patients for surgical removal of hepatic lesions is possible 
if there is a high grade or a middle grade of differentiation 
of the neoplasm (G1 or G2) and the lesions are operable, the 
patient does not suffer from right-ventricular heart failure 
(cardiac carcinoid syndrome) and non-operable metastases 
in the lymph nodes or distant metastases beyond the ab-
dominal cavity or peritoneum have not been diagnosed [7]. 
Liver transplantation can be offered to patients with NEN 
metastases in the liver who have life-threatening signs re-
lated to hormonal activity of NENs which are resistant to 
other available treatment methods and, also, in patients 
who are hormonally inactive, have generalized inoperable 
metastatic lesions in the liver, and are also non-responsive 
to previously applied available treatment forms [8]. 
Thermal ablation of the metastatic lesions in the liver 
may not only decrease or remove the neoplastic foci; how-
ever, in specific cases, it may decrease intensification or 
result in complete resolution of symptoms related to hor-
monal activity of the advanced NEN [9]. The basic method of 
reducing the signs related to hormonal activity of NENs is the 
application of somatostatin analogues (with long-term ef-
fects) once a month either in an intramuscular dose of 20–30 
mg (octreotide) or in a subcutaneous dose of 90–120 mg 
(lanreotide). Periodically, e.g. during the pre-operative pe-
riod, it may be necessary to administer (subcutaneously 
or intravenously) the preparations with short-term effects 
for prevention of a possible breakthrough related to rapid 
release of serotonin. In the event of the ineffectiveness of 
somatostatin analogues, application of IFN-α can be con-
sidered [10]. Systemic chemotherapy is recommended for 
pancreatic NEN, diffuse foregut G2 NET and G3 NEC, regard-
less of the point of origin of the neoplasm. We can choose 
streptozocin with 5-fluorouracil or doxorubicin, temozo-
lomide and capecitabine; it is also recommended to use 
cisplatin and etoposide [11]. Isotopic radiotherapy with the 
application of somatostatin analogues (DOTA-TOC, DOTA-
TATE) labelled 90Y or 177LU can be used when we deal with 
diffuse G1–2 NETs, with both active and inactive hormonal 
activity, regardless of the point of origin of the neoplasm, 
yet, with required expression of the somatostatin receptors 
confirmed with imaging tests (scintigraphy with the applica-
tion of somatostatin analogues or (68Ga-DOTA-TATE PET/ 
/CT) or an immunohistochemical test [12]. The mToR kinase 
inhibitor (everolimus) and numerous tyrosine kinase inhibi-
tors (sunitinib) provide entirely new possibilities for targeted 
treatment of the patients with advanced NENs [13]. Control 
examinations of the patients with advanced NENs include 
imaging tests (CT, MRI) and determination of the specific 
markers for this group of neoplasms (cgA and possibly spe-
cific markets for particular types of tumours) — for G1–2 
NET these tests should be performed every 3–6 months. 
Assessment of the expression of the somatostatin receptors 
(scintigraphic or with the application of 68Ga-DOTA-TATE 
PET/CT) should be carried out once in the period of 18–24 
months or earlier, depending on the results of imaging tests 
or marker levels. For G3 NEC, the above-mentioned tests 
should be performed every 2–3 months [14]. 
The percentage of five-year survivals in the metastatic 
neuroendocrine neoplasms is similar to the percentage of 
five-year survivals in other metastatic neoplasms, ranging 
from 4% in neuroendocrine carcinomas to 35% in G1 and 
G2 NETs [3]. To demonstrate how rare these neoplasms 
are, it is worth referring to the German research including 
patients from the National Centre of Neoplastic Diseases 
that gathered the data about 30 patients over a period of 
three years [15]. 
In the above-mentioned case, it is necessary to consider 
the onset of symptoms, from the causes of hospitalization 
at the Department of Laryngology related to deafness and 
hearing impairment. The neuroimaging tests performed at 
that time did not display pathologies, probably due to the 
short course of the disease. During hospitalization at the 
Department of Neurology, an ischaemic stroke of the left 
cerebellar hemisphere was diagnosed. Due to the image of 
the CSF, empirical treatment of the bacterial meningitis was 
applied. Intensified vegetative symptoms, non-responsive to 
treatment, swallowing difficulties, saturation loss suggested 
pathology within the brainstem. Taking into account the 
whole clinical image and the results of the post-mortem 
examination, it is always necessary to include rare causes 
of diseases in differential diagnostics. 
Conclusions
1. It is always necessary to include rare causes of diseases 
in differential diagnostics. 
2. The difference in the names depending on literature and 
country of origin of the article, as well as a lack of Polish 
equivalents of particular names of neoplasms consti-
tutes an additional difficulty in diagnosing MANEC. 
3. Only reliable histopathological analysis can allow detec-
tion of neoplasms from this group. 
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